| 翻訳と辞書 |
PAC-1
''This article refers to the anti-tumor molecule, and not the a2iib3 integrin activation specific antibody of the same name''
PAC-1 (first procaspase activating compound) is a synthesized chemical compound that selectively induces apoptosis, or cell suicide, in cancerous cells. PAC-1 has shown good results in mouse models and is being further evaluated for use in humans. In 2010 a published study showed PAC-1 to be safe to research dogs, and a second study published later that same year reported that a PAC-1 derivative (called S-PAC-1) was well tolerated in a small Phase I Clinical Trial of pet dogs with lymphoma. Even at low doses of S-PAC-1, tumors regressed in 1/6 dogs, and the disease was stabilized (no additional tumor growth) in 3/6 dogs. In 2011 Vanquish Oncology Inc. was founded to move PAC-1 forward to a human clinical trial, in 2013 Vanquish Oncology announced a multimillion dollar angel investment into the company, and in early 2015 a Phase 1 clinical trial of PAC-1 opened for enrollment of cancer patients.
==Function and discovery==
PAC-1 (pronounced "pack one") was discovered in Professor Paul Hergenrother's laboratory at the University of Illinois at Urbana-Champaign during a process that screened many chemicals for anti-tumor potential. This molecule, when delivered to cancer cells, signals the cells to self-destruct by activating an "executioner" protein, procaspase-3. Then, the activated executioner protein begins a cascade of events that destroys the machinery of the cell.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「PAC-1」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|